Clopidogrel use as a risk factor for poor outcomes after kidney transplantation

Area of Science:

• Nephrology
• Transplantation Medicine
• Pharmacology

Background:

• Limited data exist on clopidogrel's impact on kidney transplant outcomes.
• Understanding pre-transplant medication use is crucial for optimizing patient care.

Purpose of the Study:

• To investigate the association between pre-transplant clopidogrel use and post-transplant mortality and graft failure.
• To explore the utility of pharmacy claims data in identifying transplant prognostic markers.

Main Methods:

• Utilized a novel dataset linking national transplant registry data with pharmacy claims (2005-2010).
• Estimated risks of death and graft failure based on clopidogrel fills within 90 days or more than 90 days before transplant.

Main Results:

• Clopidogrel use within 90 days of transplant was linked to a 61% increase in mortality risk and 23% increase in graft failure risk.
• Use more than 90 days prior was associated with even higher risks (111% for death, 59% for graft loss).
• These risks were consistent across various recipient groups, including those with diabetes or cardiovascular disease.

Conclusions:

• Pre-transplant clopidogrel use is associated with significantly increased risks of post-transplant death and graft loss.
• Pharmacy claims data offer valuable prognostic insights beyond traditional transplant registry information.